氨基酶A:用于高血压管理的新型治疗标
Pragya Sharma1, Suman Sharma1, Sarvesh Paliwal1
1Department of Pharmacy, Banasthali Vidyapith, Jaipur, Rajasthan, India.
Cell biochemistry and function
|October 24, 2024
概括
氨基酶A (APA) 通过分解血管素II (AngII) 对血压调节至关重要. 它的活性变化与高血压,先兆子和激素替代疗法有关,突出显示了它在心血管健康中的作用.
科学领域:
- 生物化学 生物化学
- 生理学 生理学 生理学
- 心血管研究研究心血管研究
背景情况:
- 氨酸- ангиотензин系统 (RAS) 是理解高血压病理生理学的关键.
- 有限的研究集中在RAS中的活性,血管素II (AngII) 的分解上.
- 氨基酶A (APA) 在分解AngII方面发挥作用.
研究的目的:
- 研究氨基酶A (APA) 在调节血压中的作用.
- 在高血压条件下检查RAS激活,AngII水平和APA之间的联系.
- 探索APA活性变化在妊娠前和激素替代疗法 (HRT) 后.
主要方法:
- 对缺乏APA的动物模型进行分析,以观察血压的影响.
- 在自发高血压大鼠 (SHR) 中评估脏血管素转化酶 (ACE) 活性.
- 测量正常怀孕期间的APA活性,妊娠前的进展和HRT后的APA活性.
主要成果:
- 缺乏APA的动物患高血压,这表明APA通过AngII分解在血压调节中的关键作用.
- 在SHR中,高血压与RAS激活和ACE活性降低有关.
- 血清APA活性在早期妊娠前中增加,然后在严重情况下下降;血清APA在HRT后升高,可能是由于AngII增加.
结论:
- APA是一种通过代谢AngII.II来调节血压的关键酶.
- APA活动的调节失调与高血压和子宫前有关.
- 需要进一步的研究来阐明RAS,AngII和APA在心血管疾病中的相互作用.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
499
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
499
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
485
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
485
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
592
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
592
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
136
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
136


